Loading
A phase 2 trial of Nogapendekin alfa inbakicept, Pembrolizumab, Nivolumab in non-small-cell lung cancer and small-cell lung cancer, run by ImmunityBio, Inc., active and no longer recruiting.
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors is a phase 2 interventional study registered as NCT03228667 by ImmunityBio, Inc., with 40 participants planned, started 2018-12-11 and due to reach its primary completion in 2029-08-31. Interventions recorded: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab. Conditions listed: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ImmunityBio, Nogapendekin alfa inbakicept, Nivolumab, Non-small-cell lung cancer.
Shares ImmunityBio, Nogapendekin alfa inbakicept, Non-small-cell lung cancer.
Shares ImmunityBio, Nogapendekin alfa inbakicept.
Shares Atezolizumab, Durvalumab, Nivolumab, Pembrolizumab.
Shares Atezolizumab, Durvalumab, Nivolumab, Melanoma.
Shares Merkel cell carcinoma, Nivolumab, Head and neck squamous cell carcinoma, Melanoma.
Shares Atezolizumab, Nivolumab, Pembrolizumab, Non-small-cell lung cancer.
Shares ImmunityBio, Nogapendekin alfa inbakicept.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/